Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Psychosis during chronic levodopa
therapy triggered by the new antidepressive drug
mirtazapine.
Normann C, Hesslinger B, Frauenknecht
S, Berger M, Walden J.
Department of Psychiatry and
Psychotherapy, University of Freiburg, Germany.
We report the
case of a patient developing psychosis after the addition of
mirtazapine, a novel antidepressant enhancing serotonergic
neurotransmission, to a chronic levodopa regimen. There was complete and
rapid recovery upon low-dose clozapine treatment. To our knowledge, this
is the first published case of a mirtazapine-levodopa interaction and
the second case report of a psychosis induced by a serotonergic
antidepressant in a patient with Parkinson's disease (PD). This
phenomenon might be due to a postsynaptic serotonin receptor
supersensitization caused by low central serotonin levels in treated
PD.
Publication Types:
PMID: 9442549 [PubMed - indexed for
MEDLINE]
|